A novel glucagon-like peptide-1 (GLP-1)/Glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed Mice

Journal of Biological Chemistry

Volumn 288, Issue 49, 2013, Pages 35581-35591

  Gault, Victor A ^a   Bhat, Vikas K ^a   Irwin, Nigel ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGONIST ACTIVITY; AMINO ACID SEQUENCE; BIOLOGICAL ACTIONS; GLUCAGON-LIKE PEPTIDE-1; HYBRID PEPTIDES; THERAPEUTIC POTENTIALS;

AMINO ACIDS; GLUCOSE; POLYPEPTIDES;

PEPTIDES;

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON RECEPTOR; PLACEBO; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MIXTURE; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL MOUSE; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; LIPID DIET; LOCOMOTION; MALE; MOUSE; NONHUMAN; OBESITY; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; UPREGULATION; WEIGHT REDUCTION;

DIABETES; GLUCOSE; INSULIN; INSULIN SECRETION; OBESITY;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; CYCLIC AMP; DIET, HIGH-FAT; DIPEPTIDYL PEPTIDASE 4; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; MOLECULAR SEQUENCE DATA; OBESITY; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS;

EID: 84890275882     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.512046     Document Type: Article

References (33)

1. Murphy, K. G., and Bloom, S. R. (2006) Gut hormones and the regulation of energy homeostasis. Nature 444, 854-859
2. Sadry, S. A., and Drucker, D. J. (2013) Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425-433
3. Ionut, V., Burch, M., Youdim, A., and Bergman, R. N. (2013) Gastrointestinal hormones and bariatric surgery induced weight loss. Obesity 21, 1093-1103
4. Gribble, F. M. (2012) The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc. Nutr. Soc. 71, 456-462
5. Gault, V. A., Kerr, B. D., Harriott, P., and Flatt, P. R. (2011) Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose- lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin. Sci. 121, 107-117
6. Flatt, P. R., Bailey, C. J., and Green, B. D. (2009) Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr. Drug Metab. 10, 125-137
7. Dunning, B. E., and Gerich, J. E. (2007) The role of -cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr. Rev. 28, 253-283
8. Parker, J. A., McCullough, K. A., Field, B. C., Minnion, J. S., Martin, N. M., Ghatei, M. A., and Bloom. S. R. (2013) Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int. J. Obes. (Lond.) 37, 1391-1398
9. Gelling, R. W., Vuguin, P. M., Du, X. Q., Cui, L., Rømer, J., Pederson, R. A., Leiser, M., Sørensen, H., Holst, J. J., Fledelius, C., Johansen, P. B., Fleischer, N., McIntosh, C. H., Nishimura, E., and Charron, M. J. (2009) Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am. J. Physiol. Endocrinol. Metab. 297, E695-707
10. Deacon, C. F. (2005) What do we know about the secretion and degradation of incretin hormones Regul. Pept. 128, 117-124
11. Pospisilik, J. A., Hinke, S. A., Pederson, R. A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U., McIntosh, C. H., and Demuth, H. (2001) Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul. Pept. 96, 133-141
12. Hinke, S. A., Gelling, R. W., Pederson, R. A., Manhart, S., Nian, C., Demuth, H. U., and McIntosh, C. H. (2002) Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51, 652-661
13. Xiao, Q., Giguere, J., Parisien, M., Jeng, W., St-Pierre, S. A., Brubaker, P. L., and Wheeler, M. B. (2001) Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40, 2860-2869
14. Gault, V. A., Porter, D. W., Irwin, N., and Flatt, P. R. (2011) Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice. J. Endocrinol. 208, 265-271
15. McClenaghan, N. H., Barnett, C. R., Ah-Sing, E., Abdel-Wahab, Y. H., O'Harte, F. P., Yoon, T. W., Swanston-Flatt, S. K., and Flatt, P. R. (1996) Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45, 1132-1140
16. Flatt, P. R., and Bailey, C. J. (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/-) mice. Diabetologia 20, 573-577
17. Bhat, V. K., Kerr, B. D., Vasu, S., Flatt, P. R., and Gault, V. A. (2013) A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fatfed mice. Diabetologia 56, 1417-1424
18. Bailey, C. J., Flatt, P. R., and Atkins, T. W. (1982) Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obes. 6, 11-21
19. Hamilton, A., and Hölscher, C. (2009) Receptors for the incretin glucagon- like peptide-1 are expressed on neurons in the central nervous system. Neuroreport. 20, 1161-1166
20. Cho, Y. M., Merchant, C. E., and Kieffer, T. J. (2012) Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol. Ther. 135, 247-278
21. Baggio, L. L., and Drucker, D. J. (2007) Biology of incretins. GLP-1 and GIP. Gastroenterology 132, 2131-2157
22. Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., and Tschöp, M. H. (2010) The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6, 689-697
23. Irwin, N., Hunter, K., Montgomery, I. A., and Flatt, P. R. (2013) Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Diabetes Obes. Metab. 15, 650-659
24. Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G., Greig, N. H., and Egan, J. M. (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141, 1936-1941
25. Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., and Denaro, M. (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4. Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48, 1026-1034
26. Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., and Egan, J. M. (1999) Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42, 45-50
27. Al-Barazanji, K. A., Arch, J. R., Buckingham, R. E., and Tadayyon, M. (2000) Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes. Res. 8, 317-323
28. Wang, Q., and Brubaker, P. L. (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45, 1263-1273
29. Delmeire, D., Flamez, D., Moens, K., Hinke, S. A., Van Schravendijk, C., Pipeleers, D., and Schuit, F. (2004) Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. Biochem. Pharmacol. 68, 33-39
30. Baggio, L. L., Kim, J. G., and Drucker, D. J. (2004) Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 53, S205-S214
31. Parlevliet, E. T., de Leeuw van Weenen, J. E., Romijn, J. A., and Pijl, H. (2010) GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 299, E318-E324
32. Baggio, L. L., Huang, Q., Brown, T. J., and Drucker, D. J. (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53, 2492-2500
33. Brubaker, P. L., and Drucker, D. J. (2002) Structure-function of the glucagon receptor family of G protein-coupled receptors. The glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 8, 179-188